Search Results

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes

Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic

the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

C5aR Fluorescent Ligands: Need for new Research Tools GPCRs are one of the most important families of therapeutic Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

We hope our research will aid in the development of new therapeutic interventions for the alleviation

His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic

She has advanced the use of computational methods to meet the challenges of designing therapeutics with

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics

The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic

Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic